Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

Similar documents
CLINICAL THERAPEUTICS 6: DISEASES OF THE CENTRAL NERVOUS SYSTEM I

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

NI Formulary: Chapter 4 Central Nervous system

Neurotransmitter Systems III Neurochemistry. Reading: BCP Chapter 6

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Antidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

NERVOUS SYSTEM 1 CHAPTER 10 BIO 211: ANATOMY & PHYSIOLOGY I

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

Review of Neurochemistry What are neurotransmitters?

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

PHRM20001: Pharmacology - How Drugs Work!

- Neurotransmitters Of The Brain -

Synaptic transmission

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

PARKINSON S MEDICATION

Omar Ismail. Dana Almanzalji. Faisal Mohammad

SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults

9.98 Neuropharmacology January (IAP) 2009

Neuro Basics SLO Practice (online) Page 1 of 5

Chapter 4 ~ Central nervous system

Practical Management Of Osteoporosis

Synaptic Communication. Steven McLoon Department of Neuroscience University of Minnesota

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Advanced Neurotransmitters & Neuroglia

General Anesthesia. Mohamed A. Yaseen

How do we treat migraine? New SIGN Guidelines

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

NEUROPHYSIOLOGY, SYNAPTIC PHARMACOLOGY AND ENDOCRINOLOGY

The Nervous System Mark Stanford, Ph.D.

Treatments for migraine

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

NEURAL TISSUE (NEUROPHYSIOLOGY) PART I (A): NEURONS & NEUROGLIA

Classes of Neurotransmitters. Neurotransmitters

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Neurophysiology and Neurochemistry in PsychoGeriatrics

Medicines Formulary BNF Section 4 Central Nervous System

Pharmacotherapy for Nervous System Disorders. Department of Pharmacology Medical Faculty Lambung Mangkurat University

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Exam 2 PSYC Fall (2 points) Match a brain structure that is located closest to the following portions of the ventricular system

Study Guide Unit 2 Psych 2022, Fall 2003

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Neurotransmitters acting on G-protein coupled receptors

Part ONE Answer ALL questions. Write the correct answer CLEARLY in the answer grid provided.

Faculty of dentistry Second year CND Course CNS Drugs Dr. Ali Awadallah

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Basics of Pharmacology

What is in this leaflet

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Package leaflet: information for the user. Memantine STADA 20 mg filmomhulde tabletten. Memantine hydrochloride

Neuron types and Neurotransmitters

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

Antiepileptic agents

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

XADAGO (safinamide) oral tablet

Objectives. 1. Outline the criteria that need to be met before a molecule can be classified as neurotransmitter

Berkshire West Area Prescribing Committee Guidance

DRUGS THAT ACT IN THE CNS

BIOLOGICAL PROCESSES

Neuropathic Pain in Palliative Care

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

Neuropharmacology NOTES

Part 2: How Your Brain and Nervous System Work

Results of a one-year, retrospective medication use evaluation. Joseph Ladd, PharmD PGY-1 Pharmacy Resident BHSF Homestead Hospital

Neurotransmitters. Chemical transmission of a nerve signal by neurotransmitters at a synapse

1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective

The Nervous System. Chapter 4. Neuron 3/9/ Components of the Nervous System

Clinical Guideline for the management of inpatients with Parkinson s disease

Switching Tramacet to paracetamol alone or paracetamol and codeine

Epilepsy Medications: The Basics

Palliative Prescribing - Pain

Enhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Neural Communication. Central Nervous System Peripheral Nervous System. Communication in the Nervous System. 4 Common Components of a Neuron

PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS

2 What you need to know before you take Naramig

PETER PAZMANY CATHOLIC UNIVERSITY Consortium members SEMMELWEIS UNIVERSITY, DIALOG CAMPUS PUBLISHER

Ketamine for Pain Control in Palliative care: A Guide for Patients

1. Name the two major divisions of the nervous system and list the organs within each. Central Nervous System Peripheral Nervous System

Ch. 45 Continues (Have You Read Ch. 45 yet?) u Central Nervous System Synapses - Synaptic functions of neurons - Information transmission via nerve

Section: Chapter 5: Multiple Choice. 1. The structure of synapses is best viewed with a(n):

Chapter 4. Psychopharmacology. Copyright Allyn & Bacon 2004

Integrated Cardiopulmonary Pharmacology Third Edition

Introduction. 1 person in 20 will have an epileptic seizure at some time in their life

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Parkinson s Disease. Gillian Sare

ONZETRA XSAIL (sumatriptan) nasal powder

Pharmacology for CHEMISTS

Treatment of Alzheimer s disease

PACKAGE LEAFLET: INFORMATION FOR THE USER

Pharmacodynamics. Drugs usually elicit more than one effect. What the drug does to the body. How do drugs work? What do they do?

Package leaflet: Information for the user. Zomig 5 mg Nasal Spray zolmitriptan

Neurotransmitter Systems I Identification and Distribution. Reading: BCP Chapter 6

Brain Neurotransmitters

BEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN

Transcription:

UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2016-2017 CENTRAL NERVOUS SYSTEM PHAN6014B Time allowed: 2 hours Part ONE Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers. Part TWO Answer TWO of the THREE questions. Use a SEPARATE answer book for EACH question in Part TWO. All questions have equal weighting. Answer ALL parts of each of the individual questions you select. The mark allocation for the paper is: Part ONE carries 50% of the total mark Part TWO carries 50% of the total mark This paper consists of 13 pages in total. The following is provided: Multiple choice answer grid. Notes are not permitted in this examination. Do not turn over until you are told to do so by the Invigilator. Do not take this question paper out of the examinations room. (PHAN6014B) Module Contact: Dr Julie Sanderson, PHA Copyright of the University of East Anglia Version 1

2 PART ONE SECTION A TYPE 1 MCQ (Single Best Answer) Answer ALL questions. For each question there is ONE correct answer. Use the answer grid provided for ALL your answers. 1. In terms of volume, which ONE of the following is the largest region of the human brain? Brainstem Cerebellum Cerebrum Corpus callosum Diencephalon 2. Which ONE of the following is INCORRECT regarding 5-hydroxytryptamine (5-HT) in the human brain? It is a neurotransmitter associated with neurons of the Raphe nuclei Its synaptic activity is enhanced by selective serotonin reuptake inhibitors (SSRIs) It is synthesized in the pre-synaptic terminal of the neuron 5-HT pathways are a major target of drugs used in treatment of epilepsy 5-HT signalling is a major target of drugs used in treatment of migraine 3. Which ONE of the following is INCORRECT regarding the N-methyl-Daspartate (NMDA) receptor? It has a glutamate binding site It has a glycine binding site It has a GABA binding site It has a Mg 2+ binding site It has a polyamine binding site 4. Which ONE of the following is INCORRECT about the choroid plexus? The choroid plexus is composed of epithelial cells The choroid plexus is found only in the lateral ventricles The choroid plexus serves as a barrier between the blood and the cerebrospinal fluid (CSF) The choroid plexus displays tight junctional networks The choroid plexus prevents passive protein leakage from the blood into the intraventricular spaces

3 5. Which ONE of the following best describes the composition of a functional LAT1 transporter? 4F2 heavy chain and CD98 light chain 4F2 light chain and CD98 light chain 4F2 light chain and 4F2 heavy chain CD98 light chain and IgG heavy chain Fc domain IgG heavy chain Fc domain and CD98 light chain 6. Which ONE of the following is NOT associated with the pathophysiology of Alzheimer s disease? Amyloidogenesis Hyperphosphorylation of Tau Neurodegeneration in the basal ganglia Neurofibrillary tangles Plaque formation 7. In terms of renal and hepatic impairment, which ONE of the following is LEAST appropriate regarding the use of memantine in treatment of Alzheimer s disease? In patients with mildly impaired renal function, no dose adjustment is required In patients with moderate renal impairment, the recommended daily dose is10mg/day. If tolerated well after at least 7 days of treatment, the dose could be increased to 20mg/day according to the standard titration scheme In patients with severe renal impairment, the recommended daily dose is10mg/day Due to possible increased exposure in mild to moderate hepatic impairment, dose escalation should be performed according to individual tolerability Administration is not recommended in patients with severe hepatic impairment 8. Which ONE of the following has NOT been investigated as a drug discovery target for Alzheimer s disease? β-secretase (BACE) inhibitors Histone deacetylase (HDAC) inhibitors Monoamine oxidase (MAO) inhibitors N-Methyl-D-aspartic acid (NMDA) receptor Proton pump inhibitors TURN OVER

4 9. Which ONE of the following is a motor symptom commonly associated with Parkinson s disease? Depression Dementia Micrographia Sleep disturbance Sialorrhoea 10. Which ONE of the following best describes the pharmacological mechanism of action of rasagiline, a drug used in the treatment of Parkinson s disease? It is an irreversible inhibitor of monoamine oxidase B (MAOB) It is a selective inhibitor of dopamine reuptake It is a selective catechol-o-methyl transferase (COMT) inhibitor It increases the enzymatic production of dopamine from L-DOPA It is a DOPA decarboxylase inhibitor 11. Which ONE of the following is INCORRECT about epilepsy? According to the World Health Organisation, it accounts for 0.75% of the global burden of disease Incidence rates are lowest in children The majority of cases are idiopathic It can be secondary to a brain tumour There can be a genetic component to the disease 12. Which ONE of the following is CORRECT regarding the biosynthesis of morphine? Demethylation of reticuline gives morphine Thebaine is a precursor of dopamine Dopamine is oxidised to papaverine Reticuline is a precursor of thebaine Tyramine is the precursor of tyrosine

5 13. Mr NM comes to the pharmacy to buy a packet of co-codamol 8/500 tablets for his headaches. The counter assistant tells you that he has been buying these every few days for the past two weeks. He takes no other medication and has no other medical conditions. Which ONE of the following would be the MOST appropriate action? Sell the co-codamol Recommend he tries co-codamol and ibuprofen Refer the patient to the doctor urgently Suggest he tries to go without using co-codamol for a while and then see the doctor if there is no improvement Recommend he tries sumatriptan 14. Which ONE of the following patients may NOT be able to safely receive epidural analgesia? A pregnant female patient A female patient with haemophilia A male patient who reports suffering from a severe headache following a previous epidural injection A female patient who has had a previous deep vein thrombosis (DVT) A male patient who takes medication to manage hypertension 15. Which ONE of the following is NOT an intravenous anaesthetic? Etomidate Isoflurane Ketamine Propofol Thiopental 16. Which ONE of the following classes of drugs would stimulate the production of aqueous humour? An α2-receptor agonist A β-receptor agonist A β-receptor antagonist A muscarinic agonist A muscarinic antagonist TURN OVER

6 17. The tear film is the first barrier encountered when considering drug delivery to the eye. Which ONE of the following statements is INCORRECT regarding the tear film? Human tear volume is estimated to be 7µl The cul-de-sac can transiently contain around 30μl of administered liquid formulations Most of any topically administered ocular drug solution is washed away in the time period 30-60 minutes following administration The tear film has a rapid restoration time of 2 3 minutes Mucin in the tear film forms a hydrophilic layer for clearing debris and pathogens

7 SECTION B TYPE 2 MCQ (Extended matching questions) Neurotransmitters (F) (G) Acetylcholine Dopamine γ-aminobutyric acid (GABA) Glutamate Glycine 5-hydroxytryptamine (5-HT) Noradrenaline For each of the following statements, select the corresponding neurotransmitter from the list above. Each option may be used once, more than one, or not at all. 18. A neurotransmitter acting at ligand-gated Cl - channels that are potentiated by benzodiazepines. 19. A neurotransmitter that is depleted in Parkinson s disease from the neurons of the substantia nigra. 20. The major excitatory neurotransmitter in the central nervous system. 21. A neurotransmitter thought to cause the release of nitric oxide leading to the dilation of extracerebral blood vessels which result in throbbing pain in the head for a patient. TURN OVER

8 Epilepsy (F) (G) (H) Carbamazepine Clonazepam Gabapentin Lamotrigine Lorazepam Sodium valproate Topiramate Vigabatrin For each of the following statements, select the most appropriate anti-epileptic drug from the list above. Each option may be used once, more than once, or not at all. 22. A drug whose primary pharmacological action is to inhibit the conversion of γ- aminobutyric acid (GABA) to glutamate. 23. Mr TS is 46 years old and has requested a private conversation with you about his hair loss. He thought he was losing his hair because of his age, but it is now growing back curly. Which medication is most likely to be causing these side-effects? 24. Mrs JM is currently taking carbamazepine for focal seizures, but is not well controlled. The clinician asks for advice regarding adjuvant medication. Which medication would be most suitable?

9 Migraine (F) (G) (H) Co-codamol 8/500 tablets Eletriptan tablets Ibuprofen tablets Migraleve pink tablets Naratriptan tablets Paracetamol tablets Sumatriptan nasal spray Zolmitriptan orodispersable tablets For each of the patients described, select the most appropriate therapy from the list above. Each option may be used once, more than once, or not at all. 25. A migraine sufferer who has very intense, quick onset, headaches at the start of the attack, together with lots of nausea and vomiting. 26. A migraine sufferer who has slow onset migraine which lasts for two days with moderate intensity. 27. A migraine sufferer with uncontrolled blood pressure and allergy to aspirin. TURN OVER

10 Analgesia (F) (G) Amitriptyline Aspirin Codeine Diamorphine Fentanyl Methadone Naproxen For each of the patients described, select the most suitable therapy from the list above. Each option maybe used once, more than once or not at all. 28. Mrs ST, a 55 year old lady with no previous medical history, has recently fractured her wrist. She has been taking paracetamol and ibuprofen for analgesia, though she tells you that the pain is not being managed. 29. Mr PH, a 65 year old man with no previous medical history, has been diagnosed with shingles and has been experiencing neuropathic pain. 30. Mrs WY, a 74 year old lady diagnosed with palliative oesophageal cancer, is currently taking paracetamol and oral morphine for her pain. She has been having trouble swallowing and the doctors want to switch her analgesia to a patch. END OF PART ONE

11 PART TWO Answer TWO of the THREE questions. Use a SEPARATE answer book for EACH question. 31. Answer ALL parts (a) to (c). (a) Critically appraise the role of passive and active mechanisms for drug transport across the blood brain barrier. Use graphs and diagrams in your answer to illustrate your point. [50%] You are a basic grade hospital pharmacist on your rotation of the neurology wards. You encounter Mr GH who was admitted earlier this morning for a chest infection which was due to aspiration. Mr GH is 75 years old with a diagnosis of Parkinson s disease. His medication history is co-beneldopa 25/100, four capsules three times a day and metoclopramide 10mg tablets three times a day when required. The foundation year doctor would like to start him on metronidazole and amoxicillin three times a day for the chest infection. (b) Co-beneldopa is a combination product of levodopa and benserazide. Explain why levodopa is administered in preference to dopamine and the role of benserazide in this combination product. [30%] (c) Discuss the pharmaceutical issues that should be investigated to ensure that Mr GH s medication is appropriately managed during his admission and that he is appropriately prepared for discharge. [20%] TURN OVER

12 32. Answer ALL parts (a) to (d). (a) Describe the neurochemical changes that occur in relation to acetylcholinedependent signalling in the pathophysiology of Alzheimer s disease. [20%] (b) How do acetylcholinesterase inhibitors affect cholinergic signalling? [15%] (c) Donepezil is an acetylcholinesterase inhibitor that is used in the treatment of Alzheimer s disease. (i) Show reagents and conditions for the following two steps (A and B) in donepezil synthesis. [20%] (ii) Suggest reasons why the drug is marketed as the racemate rather than a single enantiomer. [10%] (d) Mrs CP is a 76 year old lady, who has received a new prescription for donepezil 10mg daily. She is also currently prescribed: Propranolol 10mg three times daily, Paracetamol 1g QDS prn. (i) Mrs CP has been experiencing symptoms such as nausea, sickness, dizziness and fatigue since starting her new medication. What might be the cause? [20%] (ii) Discuss your possible interventions. [15%]

13 33. Answer ALL parts (a) to (e). (a) Describe the physiological transmission of a pain signal. [30%] (b) Explain how states of hyperalgesia could develop. [10%] (c) During pain signal transmission, explain where opioid drugs could exert their effect. [15%] (d) For the following three molecules, discuss with reference to the Snyder theory, whether they would act as agonists or antagonists or show mixed behaviour at opioid receptors. Use diagrams to illustrate your answer. HO HO HO N O N N O OH O H 1 2 3 [20%] (e) Compare and contrast, with examples, two different approaches currently being investigated to develop opioid analgesics with reduced side effects. [25%] END OF PAPER